Brokerages expect Bruker Corporation (NASDAQ:BRKR) to post $414.24 million in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Bruker Corporation’s earnings, with the highest sales estimate coming in at $420.50 million and the lowest estimate coming in at $402.00 million. Bruker Corporation posted sales of $393.90 million during the same quarter last year, which suggests a positive year-over-year growth rate of 5.2%. The company is scheduled to announce its next earnings report on Wednesday, November 1st.
According to Zacks, analysts expect that Bruker Corporation will report full year sales of $414.24 million for the current financial year, with estimates ranging from $1.68 billion to $1.77 billion. For the next financial year, analysts expect that the business will report sales of $1.76 billion per share, with estimates ranging from $1.70 billion to $1.80 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Bruker Corporation.
Bruker Corporation (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.03. Bruker Corporation had a net margin of 9.65% and a return on equity of 26.66%. The firm had revenue of $414.90 million for the quarter, compared to the consensus estimate of $384.75 million. During the same period last year, the firm earned $0.20 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis.
BRKR has been the topic of a number of recent analyst reports. BidaskClub upgraded shares of Bruker Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. Wells Fargo & Co cut shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a research note on Wednesday, July 12th. Zacks Investment Research upgraded shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research note on Thursday, July 6th. Barclays PLC restated an “equal weight” rating and set a $30.00 price objective (up from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Finally, Cowen and Company restated a “hold” rating and set a $29.00 price objective on shares of Bruker Corporation in a research note on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. Bruker Corporation presently has a consensus rating of “Hold” and a consensus target price of $27.00.
In other Bruker Corporation news, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the sale, the vice president now directly owns 60,524 shares in the company, valued at $1,813,904.28. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Frank H. Laukien purchased 2,335 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average price of $27.39 per share, for a total transaction of $63,955.65. Following the completion of the transaction, the chief executive officer now owns 37,791,386 shares of the company’s stock, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. 35.20% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in Bruker Corporation by 2.9% in the first quarter. Vanguard Group Inc. now owns 9,832,452 shares of the medical research company’s stock worth $229,391,000 after acquiring an additional 277,111 shares in the last quarter. FMR LLC raised its position in Bruker Corporation by 26.4% in the first quarter. FMR LLC now owns 7,146,000 shares of the medical research company’s stock worth $166,716,000 after acquiring an additional 1,491,140 shares in the last quarter. BlackRock Inc. raised its position in Bruker Corporation by 3.0% in the second quarter. BlackRock Inc. now owns 4,747,514 shares of the medical research company’s stock worth $136,918,000 after acquiring an additional 139,792 shares in the last quarter. Boston Partners raised its position in Bruker Corporation by 3.6% in the second quarter. Boston Partners now owns 2,773,019 shares of the medical research company’s stock worth $79,973,000 after acquiring an additional 96,791 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in Bruker Corporation by 6.8% in the second quarter. Victory Capital Management Inc. now owns 1,930,209 shares of the medical research company’s stock worth $55,667,000 after acquiring an additional 123,322 shares in the last quarter. Hedge funds and other institutional investors own 65.42% of the company’s stock.
Bruker Corporation (NASDAQ:BRKR) traded down 0.20% during trading on Thursday, hitting $29.36. 359,011 shares of the stock were exchanged. Bruker Corporation has a 12 month low of $19.59 and a 12 month high of $30.23. The stock’s 50 day moving average price is $28.57 and its 200 day moving average price is $26.57. The stock has a market cap of $4.66 billion, a P/E ratio of 29.27 and a beta of 1.10.
The firm also recently declared a quarterly dividend, which was paid on Friday, September 22nd. Shareholders of record on Tuesday, September 5th were given a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.54%. The ex-dividend date of this dividend was Thursday, August 31st. Bruker Corporation’s dividend payout ratio (DPR) is presently 16.00%.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.